1. Home
  2. NVAX vs PLUS Comparison

NVAX vs PLUS Comparison

Compare NVAX & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • PLUS
  • Stock Information
  • Founded
  • NVAX 1987
  • PLUS 1990
  • Country
  • NVAX United States
  • PLUS United States
  • Employees
  • NVAX N/A
  • PLUS N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • PLUS Retail: Computer Software & Peripheral Equipment
  • Sector
  • NVAX Health Care
  • PLUS Technology
  • Exchange
  • NVAX Nasdaq
  • PLUS Nasdaq
  • Market Cap
  • NVAX 2.0B
  • PLUS 2.6B
  • IPO Year
  • NVAX 1995
  • PLUS 1996
  • Fundamental
  • Price
  • NVAX $9.76
  • PLUS $96.76
  • Analyst Decision
  • NVAX Buy
  • PLUS Hold
  • Analyst Count
  • NVAX 6
  • PLUS 1
  • Target Price
  • NVAX $17.83
  • PLUS $90.00
  • AVG Volume (30 Days)
  • NVAX 7.2M
  • PLUS 100.1K
  • Earning Date
  • NVAX 11-07-2024
  • PLUS 11-05-2024
  • Dividend Yield
  • NVAX N/A
  • PLUS N/A
  • EPS Growth
  • NVAX N/A
  • PLUS N/A
  • EPS
  • NVAX N/A
  • PLUS 4.08
  • Revenue
  • NVAX $987,667,000.00
  • PLUS $2,195,665,000.00
  • Revenue This Year
  • NVAX N/A
  • PLUS $5.69
  • Revenue Next Year
  • NVAX N/A
  • PLUS $4.68
  • P/E Ratio
  • NVAX N/A
  • PLUS $24.00
  • Revenue Growth
  • NVAX N/A
  • PLUS 0.56
  • 52 Week Low
  • NVAX $3.53
  • PLUS $53.54
  • 52 Week High
  • NVAX $23.86
  • PLUS $102.99
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 36.20
  • PLUS 52.65
  • Support Level
  • NVAX $9.52
  • PLUS $96.35
  • Resistance Level
  • NVAX $10.63
  • PLUS $99.25
  • Average True Range (ATR)
  • NVAX 0.57
  • PLUS 2.09
  • MACD
  • NVAX -0.12
  • PLUS -0.38
  • Stochastic Oscillator
  • NVAX 9.97
  • PLUS 28.23

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

About PLUS ePlus inc.

ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.

Share on Social Networks: